NYSE:RMDMedical Equipment
Assessing ResMed (RMD) Valuation After CEO Share Sale And Sector Pressures
ResMed (RMD) is back in focus after CEO Michael Farrell sold about US$1.25 million of stock under a pre arranged trading plan. This move coincided with a 2% share decline.
See our latest analysis for ResMed.
Beyond the CEO sale and today’s 2% move, ResMed’s share price has been under pressure in recent weeks, with a 7 day share price return of 8.82% and a 30 day share price return of 8.69%, while the 1 year total shareholder return of 3.53% points to softer recent momentum compared with the...